|
1
|
Basha R, Connelly SF, Sankpal UT, Nagaraju
GP, Patel H, Vishwanatha JK, Shelake S, Tabor-Simecka L, Shoji M,
Simecka JW and El-Rayes B: Small molecule tolfenamic acid and
dietary spice curcumin treatment enhances antiproliferative effect
in pancreatic cancer cells via suppressing Sp1, disrupting NF-κB
translocation to nucleus and cell cycle phase distribution. J Nutr
Biochem. 31:77–87. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louvet C and Philip PA: Accomplishments in
2007 in the treatment of metastatic pancreatic cancer. Gastrointest
Cancer Res. 2:S37–S41. 2008.PubMed/NCBI
|
|
3
|
Lee C, He H, Jiang Y, Di Y, Yang F, Li J,
Jin C and Fu D: Elevated expression of tumor miR-222 in pancreatic
cancer is associated with Ki67 and poor prognosis. Med Oncol.
30:7002013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shi X, Liu S, Kleeff J, Friess H and
Büchler MW: Acquired resistance of pancreatic cancer cells towards
5-Fluorouracil and gemcitabine is associated with altered
expression of apoptosis-regulating genes. Oncology. 62:354–362.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang W, Zhao S, Jiang X, Zhang E, Hu G,
Hu B, Zheng P, Xiao J, Lu Z, Lu Y, et al: The circadian clock gene
Bmal1 acts as a potential anti-oncogene in pancreatic cancer by
activating the p53 tumor suppressor pathway. Cancer Lett.
371:314–325. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li HL, Li JL, Shi BL and Chen F:
MicroRNA-296 targets AKT2 in pancreatic cancer and functions as a
potential tumor suppressor. Mol Med Rep. 16:466–472. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu JH, Wu J, Pei XC, Tan ZJ, Shi JQ and
Lubman DM: Annexin A10 is a candidate marker associated with the
progression of pancreatic precursor lesions to adenocarcinoma. PLoS
One. 12:e01750392017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berindan-Neagoe I and Calin GA: Molecular
pathways: microRNAs, cancer cells, and microenvironment. Clin
Cancer Res. 20:6247–6253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen WY, Liu WJ, Zhao YP, Zhou L, Zhang
TP, Chen G and Shu H: Induction, modulation and potential targets
of miR-210 in pancreatic cancer cells. Hepatobiliary Pancreat Dis
Int. 11:319–324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu Y, Ou Y, Wu K, Chen Y and Sun W:
miR-143 inhibits the metastasis of pancreatic cancer and an
associated signaling pathway. Tumour Biol. 33:1863–1870. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kawaguchi T, Komatsu S, Ichikawa D,
Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T,
Hirajima S, et al: Clinical impact of circulating miR-221 in plasma
of patients with pancreatic cancer. Br J Cancer. 108:361–369. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qin Y, Dang X, Li W and Ma Q: miR-133a
functions as a tumor suppressor and directly targets FSCN1 in
pancreatic cancer. Oncol Res. 21:353–363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao G, Zhang JG, Liu Y, Qin Q, Wang B,
Tian K, Liu L, Li X, Niu Y, Deng SC and Wang CY: miR-148b functions
as a tumor suppressor in pancreatic cancer by targeting AMPKα1. Mol
Cancer Ther. 12:83–93. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen D, Li SG, Chen JY and Xiao M: MiR-183
maintains canonical Wnt signaling activity and regulates growth and
apoptosis in bladder cancer via targeting AXIN2. Eur Rev Med
Pharmacol Sci. 22:4828–4836. 2018.PubMed/NCBI
|
|
15
|
Sun X, Xu Y, Zhang S, Li X and Wang Y,
Zhang Y, Zhao X, Li Y and Wang Y: MicroRNA-183 suppresses the
vitality, invasion and migration of human osteosarcoma cells by
targeting metastasis-associated protein 1. Exp Ther Med.
15:5058–5064. 2018.PubMed/NCBI
|
|
16
|
Zhang XL, Xu G, Zhou Y and YAN JJ:
MicroRNA-183 promotes the proliferation and metastasis of renal
cell carcinoma through targeting Dickkopf-related protein 3. Oncol
Lett. 15:6003–6008. 2018.PubMed/NCBI
|
|
17
|
Cheng Y, Xiang G, Meng Y and Dong R:
MiRNA-183-5p promotes cell proliferation and inhibits apoptosis in
human breast cancer by targeting the PDCD4. Reprod Biol.
16:225–233. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huangfu L, Liang H, Wang G, Su X, Li L, Du
Z, Hu M, Dong Y, Bai X, Liu T, et al: miR-183 regulates autophagy
and apoptosis in colorectal cancer through targeting of UVRAG.
Oncotarget. 7:4735–4745. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang M, Liu R, Li X, Liao J, Pu Y, Pan E,
Yin L and Wang Y: miRNA-183 suppresses apoptosis and promotes
proliferation in esophageal cancer by targeting PDCD4. Mol Cells.
37:873–880. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang L, Quan H, Wang S, Li X and Che X:
MiR-183 promotes growth of non-small cell lung cancer cells through
FoxO1 inhibition. Tumour Biol. 36:8121–8126. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fan D, Wang Y, Qi P, Chen Y, Xu P, Yang X,
Jin X and Tian X: MicroRNA-183 functions as the tumor suppressor
via inhibiting cellular invasion and metastasis by targeting MMP-9
in cervical cancer. Gynecol Oncol. 141:166–174. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hanci V, Yurdakan G, Yurtlu S, Turan IÖ
and Sipahi EY: Protective effect of dexmedetomidine in a rat model
of α-naphthylthiourea-induced acute lung injury. J Surg Res.
178:424–430. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han B, Jiang P, Li ZX, Yu Y, Huang T, Ye X
and Li X: Coptisine-induced apoptosis in human colon cancer cells
(HCT-116) is mediated by PI3K/Akt and mitochondrial-associated
apoptotic pathway. Phytomedicine. 48:152–160. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu J, Li A, Hong SM, Hruban RH and Goggins
M: MicroRNA alterations of pancreatic intraepithelial neoplasias.
Clin Cancer Res. 18:981–992. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou L, Zhang WG, Wang DS, Tao KS, Song WJ
and Dou KF: MicroRNA-183 is involved in cell proliferation,
survival and poor prognosis in pancreatic ductal adenocarcinoma by
regulating Bmi-1. Oncol Rep. 32:1734–1740. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu YY, Zheng JY, Liu J, Huang CL, Zhang W
and Zeng Y: miR-183 induces cell proliferation, migration, and
invasion by regulating PDCD4 expression in the SW1990 pancreatic
cancer cell line. Biomed Pharmacother. 70:151–157. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miao F, Zhu J, Chen Y, Tang N, Wang X and
Li X: MicroRNA-183-5p promotes the proliferation, invasion and
metastasis of human pancreatic adenocarcinoma cells. Oncol Lett.
11:134–140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ni S, Wang H, Zhu X, Wan C, Xu J, Lu C,
Xiao L, He J, Jiang C, Wang W and He Z: CBX7 suppresses cell
proliferation, migration, and invasion through the inhibition of
PTEN/Akt signaling in pancreatic cancer. Oncotarget. 8:8010–8021.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi X, Gu HT, Lin SB, Zhang Y, Yang J and
Qian CJ: Abnormal expression of PTEN and PIK3CA in
pemetrexed-resistant human pancreatic cancer cell line Patu8988.
Genet Mol Res. 15:2016. View Article : Google Scholar
|
|
30
|
Wang L, Yu ZR, Ren SY, Song JK, Wang JH
and Du GH: Metabolic reprogramming in colon cancer reversed by DHTS
through regulating PTEN/AKT/HIF1α mediated signal pathway. Biochim
Biophys Acta Gen Subj. 1862:2281–2292. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu L, Long H, Wu Y, Li H, Dong L, Zhong
JL, Liu Z, Yang X, Dai X, Shi L, et al: HRD1-mediated PTEN
degradation promotes cell proliferation and hepatocellular
carcinoma progression. Cell Signal. 50:90–99. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lim HJ, Wang X, Crowe P, Goldstein D and
Yang JL: Targeting the PI3K/PTEN/AKT/mTOR pathway in treatment of
sarcoma cell lines. Anticancer Res. 36:5765–5771. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu XX, Cao LY, Chen X, Xiao J, Zou Y and
Chen Q: PTEN inhibits cell proliferation, promotes cell apoptosis,
and induces cell cycle arrest via downregulating the PI3K/AKT/hTERT
pathway in lung adenocarcinoma A549 cells. Biomed Res Int.
2016:24768422016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang LL, Hao S, Zhang S, Guo LJ, Hu CY,
Zhang G, Gao B, Zhao JJ, Jiang Y, Tian WG, et al: PTEN/PI3K/AKT
protein expression is related to clinicopathologic features and
prognosis in breast cancer with axillary lymph node metastases. Hum
Pathol. 61:49–57. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mynhardt C, Damelin LH, Jivan R, Peres J,
Prince S, Veale RB and Mavri-Damelin D: Metformin-induced
alterations in nucleotide metabolism cause 5-fluorouracil
resistance but gemcitabine susceptibility in oesophageal squamous
cell carcinoma. J Cell Biochem. 119:1193–1203. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Amponsah PS, Fan P, Bauer N, Zhao Z,
Gladkich J, Fellenberg J and Herr I: microRNA-210 overexpression
inhibits tumor growth and potentially reverses gemcitabine
resistance in pancreatic cancer. Cancer Lett. 388:107–117. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma J, Fang B, Zeng F, Ma C, Pang H, Cheng
L, Shi Y, Wang H, Yin B, Xia J and Wang Z: Down-regulation of
miR-223 reverses epithelial-mesenchymal transition in
gemcitabine-resistant pancreatic cancer cells. Oncotarget.
6:1740–1749. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liang C, Wang Z, Li YY, Yu BH, Zhang F and
Li HY: miR-33a suppresses the nuclear translocation of beta-catenin
to enhance gemcitabine sensitivity in human pancreatic cancer
cells. Tumour Biol. 36:9395–9403. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wei X, Wang W, Wang L, Zhang Y, Zhang X,
Chen M, Wang F, Yu J, Ma Y and Sun G: MicroRNA-21 induces
5-fluorouracil resistance in human pancreatic cancer cells by
regulating PTEN and PDCD4. Cancer Med. 5:693–702. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang W, Zhao L, Wei X, Wang L, Liu S, Yang
Y, Wang F, Sun G, Zhang J, Ma Y, et al: MicroRNA-320a promotes 5-FU
resistance in human pancreatic cancer cells. Sci Rep. 6:276412016.
View Article : Google Scholar : PubMed/NCBI
|
